Guidelines for Withdrawal Seizures
Alcohol Withdrawal Seizures
Benzodiazepines are the only proven therapy to prevent seizures and reduce mortality from alcohol withdrawal, and should be administered immediately to all patients at risk. 1
Risk Assessment and Prevention
- Patients with prior withdrawal seizures or delirium tremens require hospital admission due to high risk of life-threatening complications 1
- Individuals consuming >80 g of alcohol daily for ≥10 years should be managed as inpatients 1
- Benzodiazepines are the only medications with proven efficacy for preventing alcohol withdrawal seizures; anticonvulsants such as phenytoin or carbamazepine are ineffective and should not be used 1, 2
First-Line Treatment
Long-acting benzodiazepines provide superior seizure protection:
- Diazepam 5-10 mg IV/PO every 6-8 hours is the preferred agent due to its rapid onset, long half-life, and self-tapering effect that provides smoother withdrawal coverage 1, 3, 4
- Chlordiazepoxide 25-100 mg PO every 4-6 hours is an effective alternative long-acting option 1, 5
Short-acting benzodiazepines are preferred in specific populations:
- Lorazepam 1-4 mg IV/PO/IM every 4-8 hours should be used in elderly patients, those with hepatic dysfunction, respiratory compromise, or recent head trauma 1
- The belief that diazepam must be avoided in liver disease is unfounded—symptom-triggered dosing is safe when monitored appropriately 1, 4
Critical Adjunctive Treatment
Thiamine must be administered BEFORE any glucose-containing IV fluids to prevent Wernicke encephalopathy 1, 3:
- Prophylactic dosing: 100-300 mg/day PO or IV 1
- Therapeutic dosing for established Wernicke encephalopathy: 100-500 mg/day IV 1
Treatment Duration and Monitoring
- Limit benzodiazepine treatment to 10-14 days to prevent iatrogenic dependence 1, 5
- Do not discontinue benzodiazepines prematurely—treat until complete symptom resolution, which may extend beyond 72 hours 1
- Use CIWA-Ar scores to guide treatment intensity: scores >8 indicate moderate withdrawal requiring treatment, scores ≥15 indicate severe withdrawal requiring aggressive management 1, 3
Management of Active Seizures
- Benzodiazepines are the primary treatment for active alcohol withdrawal seizures through GABA activation 1
- Phenytoin has no evidence of effectiveness for preventing withdrawal seizures and should not be used 2
- Anticonvulsants worsen outcomes and may increase seizure risk 1
Common Pitfalls
- Never use antipsychotics as monotherapy—they lower seizure threshold and increase mortality 1, 6
- Haloperidol 0.5-5 mg may be added as adjunctive therapy for severe agitation in delirium tremens, but only alongside adequate benzodiazepines 1
- Phenobarbital may be considered when benzodiazepines are unavailable, but evidence in the ED setting is limited 2, 7
Benzodiazepine Withdrawal Seizures
Benzodiazepine withdrawal seizures occur with abrupt discontinuation and require gradual tapering to prevent.
Risk Factors
- Withdrawal seizures occur with short, medium, and long half-life benzodiazepines if discontinued abruptly 8
- High-dose, long-term use (typically >3 months) carries the highest risk, but seizures have been reported with <15 days of use at therapeutic doses 8, 9
- Almost all withdrawal seizures are generalized tonic-clonic, with severity ranging from single episodes to status epilepticus, coma, and death 8
Prevention Strategy
Clinicians should not discontinue benzodiazepines abruptly in patients who are likely physically dependent and at risk of withdrawal 9:
- Replace short-acting agents with long-acting benzodiazepines (e.g., diazepam) before initiating taper 10
- Taper can be done faster in hospital settings for high-dose abusers, but must be done more slowly in outpatient settings for therapeutic-dose users 8
- Tailor tapering strategies to each patient and adjust based on patient response 9
Treatment Approach
- Utilize shared decision-making and engage in ongoing risk-benefit assessment 9
- Offer adjunctive psychosocial interventions to support successful tapering 9
- Most patients can be managed on an outpatient basis with appropriate monitoring 10
Barbiturate Withdrawal Seizures
Barbiturate withdrawal requires hospitalization and phenobarbital loading for patients at risk.
Indications for Hospital Admission
Admit patients who have taken: 10
- >0.4 g/day of secobarbital (or equivalent) for ≥90 days
- >0.6 g/day of secobarbital (or equivalent) for ≥30 days
- Any patient with prior withdrawal seizures or delirium
Treatment Protocol
- Phenobarbital loading is the recommended treatment for barbiturate withdrawal 10
- Gradual dose tapering is essential to prevent seizures 10
- Faster tapering can be done in hospital settings with close monitoring 8
Pharmacokinetics Relevant to Withdrawal
- Long-acting barbiturates (e.g., phenobarbital) have smaller volumes of distribution and 20-25% renal excretion, making them more amenable to management 11
- Short-acting barbiturates (e.g., pentobarbital) are highly lipophilic with minimal renal excretion, requiring different management strategies 11
Status Epilepticus Management (Non-Withdrawal)
For refractory status epilepticus after benzodiazepine failure, fosphenytoin, levetiracetam, or valproate may be used with similar efficacy. 11
Second-Line Agents (After Benzodiazepines)
Level A recommendation: Emergency physicians should administer an additional antiepileptic medication in patients with refractory status epilepticus who have failed benzodiazepines 11
Level B recommendation: Administer IV phenytoin, fosphenytoin, or valproate 11:
- Valproate 20-30 mg/kg IV at maximum rate of 10 mg/kg/min is at least as effective as phenytoin with potentially fewer adverse effects 11
- Fosphenytoin has similar efficacy to phenytoin with reduced injection site complications 11
Level C recommendation: Consider IV levetiracetam, propofol, or barbiturates 11
Key Distinction
This guidance applies to status epilepticus from causes OTHER than withdrawal syndromes—for withdrawal-related seizures, benzodiazepines remain the sole evidence-based treatment 11, 1